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ABSTRACT 
Objective: To study the prevalence and severity of possible drug-drug interactions in the department of pediatrics.  
Methods: Case records of the in-patients of the pediatrics department from the medical records department were included and the records of the 
ambulatory patients were excluded from the study. All the collected cases were subjected to check for the drug-drug interactions by using the 
software micromedex 2.0 and the interactions were categorized based on the severity into minor, moderate and major.  
Results: A total of 142 cases were screened for possible drug-drug interactions (DDIs) and among them 76 cases were observed to be with possible 
DDIs.  The prevalence was found to be 53.5% in this study. Majority of the cases with possible DDIs were observed to be in females. Results of the 
age wise categorization revealed that majority of the possible DDIS were observed in children (2-12 y) followed by the infants (1 mo–2 y). The drug 
combinations amikacin+ampicillin, paracetamol+phenytoin and ofloxacin+ondansetron were found to be the frequently observed possible DDIs of 
minor, moderate and major severities respectively.  
Conclusion: Majority of the possible DDIs were of moderate severity followed by major. Clinical pharmacists should take the responsibility in 
assisting the pediatricians for screening the possible DDIs in the prescriptions there by preventing them and providing a better pharmaceutical care 
for the pediatric population.  
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Drug-drug interactions (DDIs) can be defined as the modification of 
the pharmacological or clinical response to a drug due to the 
concomitant administration of another drug [1]. Age, polypharmacy, 
concurrent disease conditions are some of the risk factors associated 
with DDIs. The prevalence of DDIs in various countries was reported 
in between 19.3-88.8%. In terms of a rationale prescription, DDIs 
have become a major clinical concern and they may tend to cause 
adverse events majorly in the hospitalized patients where we used 
to observe the polypharmacy in their prescriptions [2-10]. Careful 
detection and monitoring of DDIs can enhance the quality and safety 
of drug therapy. DDIs increase the duration of hospital stay and even 
the health care costs too [11-15].  
DDIs have attained a great attention from the scientific, regulatory 
and healthcare communities globally. Majority of the studies 
investigated the possible DDIs in different specialties like general 
medicine, oncology, cardiology, pulmonology and psychiatry where 
the information is just restricted to the adult population [16-23]. 
Very few studies were performed in the pediatrics specialty and 
hence, in this study we made an attempt to study the prevalence and 
severity of possible drug-drug interactions in pediatrics specialty. 
MATERIALS AND METHODS 
The present study was a retrospective cross-sectional study, 
conducted at Konaseema Institute of Medical Sciences (KIMS), 
Amalapuram, Andhra Pradesh, India. This study was approved by 
the institutional ethics committee (No: 97/2015). Case records of 
the in-patients of the pediatrics department from the medical 
records department were included and the records of the 
ambulatory patients were excluded from the study. All the collected 
cases were subjected to check for the drug-drug interactions by 
using the software micromedex 2.0 and the interactions were 
categorized based on the severity into minor, moderate and major 
[24, 25]. 
Statistical analysis 
SPSS 21.0 was used to perform the statistical analysis. Chi square 
test was performed and p-values were obtained at 95% confidence 
interval for finding the statistical significance (p<0.05). 
RESULTS 
Table 1 represents the gender wise categorization of the cases in the 
department of pediatrics included in the study. A total of 142 cases 
were screened for possible drug-drug interactions out of which 75 
(52.8%) were found to be males and 67 (47.2%) were found to be 
females. Among the 142 cases which were screened for detecting the 
possible drug-drug interactions, about 76 cases were observed with 
possible drug-drug interactions and the prevalence was found to be 
53.5%. Among the 76 cases observed with possible drug-drug 
interactions, about 34 (44.7%) were found to be males and 42 
(55.3%) were found to be females. 
 
Table 1: Gender wise categorization of cases included in the study 
Gender Cases observed with interactions (%) Cases observed without interactions (%) Total (%) χ2-value p-value 
Male 34 (44.7) 41 (62.1) 75 (52.8) 4.28 0.03* 
Female 42 (55.3) 25 (37.9) 67 (47.2) 
Total 76 (100) 66 (100) 142 (100) 
*indicates statistically significant 
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Table 2 represents the age wise categorization of patients observed 
with possible drug-drug interactions. The patients in the age group 
2-12 y (children) was observed to be with high a prevalence rate 
(72.3%) followed by the age group 1month-2years (infants) with a 
prevalence rate of 14.5%. 
Table 3 represents the categorization of patients observed with 
drug-drug interactions based on duration. Majority of the patients 
who were observed with possible drug-drug interactions were 
found to be stayed for 1-5 d (50%). 
Table 4 represents the categorization of prescriptions observed with 
drug-drug interactions based on polypharmacy in the pediatrics 
department. About 19 (25%) prescriptions were observed to be 
with major polypharmacy, about 37 (48.7%) prescriptions were 
observed to be with moderate polypharmacy and about 20 (26.3%) 
prescriptions were observed to be with minor polypharmacy. 
Table 5 and fig. 1 represents the severity of drug-drug interactions 
in the pediatrics department. A total of 136 possible drug-drug 
interactions were observed in this department out of which 21 
(15.4%) were of minor severity, 70 (51.5%) were of moderate 
severity and 45 (33.1%) were of major severity. 
Table 6 represents the most frequently observed possible minor, 




Fig. 1: Severity of the drug-drug interactions in the study 
  
Table 2: Age wise categorization of patients observed with drug-drug interactions 
Age group Male (%) Female (%) Total (%) 
Neonates (1 d-1 mo) 2 (5.9) 3 (7.1) 5 (6.6) 
Infants (1 mo-2 y) 4 (11.8) 7 (16.7) 11 (14.5) 
Children (2-12 y) 25 (73.5) 30 (71.4) 55 (72.3) 
Adolescents (12-16 y) 3 (8.8) 2 (4.8) 5 (6.6) 
Total 34 (100) 42 (100) 76 (100) 
 
Table 3: Categorization of patients observed with DDIs based on duration of stay 
Duration of stay (in days) Male (%) Female (%) Total (%) 
1-5 15 (44.1) 23 (54.7) 38 (50) 
6-10 14 (41.2) 15 (35.7) 29 (38.3) 
11-15 4 (11.8) 2 (4.8) 6 (7.8) 
16-20 1 (2.9) 2 (4.8) 3 (3.9) 
Total  34 (100) 42 (100) 76 (100) 
 
Table 4: Categorization of prescriptions observed with DDIs based on polypharmacy 
Type of polypharmacy Male (%) Female (%) Total (%) 
Minor (3-5 drugs) 8 (23.5) 12 (28.6) 20 (26.3) 
Moderate (6-8 drugs) 17 (50) 20 (47.6) 37 (48.7) 
Major (≥ 9 drugs) 9 (26.5) 10 (23.8) 19 (25) 
Total 34 (100) 42 (100) 76 (100) 
 
Table 5: Severity of the drug-drug interactions 
Severity Male (%) Female (%) Total (%) χ2-value p-value 
Minor 7 (11.5) 14 (18.7) 21 (15.4) 4.83 0.089 
Moderate 28 (45.9) 42 (56) 70 (51.5) 
Major 26 (42.6) 19 (25.3) 45 (33.1) 
Total 61 (100) 75 (100) 136 (100) 
 
Table 6: Most frequently observed possible DDIs 
Minor Moderate Major 
Amikacin+Ampicillin Paracetamol+Phenytoin Ofloxacin+Ondansetron 
Amikacin+Piperacillin Furosemide+Hydrocortisone Metronidazole+Ondansetron 
Carbamazepine+Clobazam Ondansetron+Tramadol Midazolam+Phenobarbital 
 
DISCUSSSION 
A total of 142 cases were screened for possible drug-drug interactions 
(DDIs) and among them 76 cases were observed to be with possible 
DDIs. The prevalence was found to be 53.5% in this study. 
Majority of the cases with possible DDIs were observed to be in 
females. Results of the age wise categorization revealed that majority 
of the possible DDIS were observed in children (2-12 y) followed by 
the infants (1 mo–2 y). Majority of the patients who were observed 
with possible DDIs were observed to be stay for duration of 1-5 d 
(50%) followed by 6-10 d (38.3%).  
In this study, majority of the prescriptions were found to be with 
moderate polypharmacy followed by minor polypharmacy. The 
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severity of the majority of the possible DDIs in this study was 
observed to be moderate. This result was found to be similar with 
the study done by Mohammad Ismail et al. [16] and Qorraj-Bytyqi et 
al. [25]. The drug combinations amikacin+ampicillin, paracetamol 
+phenytoin and ofloxacin+ondansetron were found to be the 
frequently observed possible DDIs of minor, moderate and major 
severities respectively.  
CONCLUSION 
In this study, the prevalence of possible DDIs was found to be 53.5%. 
Polypharmacy was associated with the occurrence of possible DDIs 
and in this study majority of the possible DDIs were observed in the 
prescriptions with moderate polypharmacy. Majority of the possible 
DDIs were of moderate severity followed by major that indicates 
that there is a need for the screening of possible DDIs. Clinical 
pharmacists should take the responsibility in assisting the 
paediatricians for screening the possible DDIs in the prescriptions 
thereby preventing them and providing a better pharmaceutical care 
for the pediatric population.  
LIMITATION 
This study with a prospective type of approach along with the 
involvement of other health care professionals would show a 
significant impact in screening the clinically encountered drug-drug 
interactions for providing the better pharmaceutical care for the 
patients by the direct involvement of the clinical pharmacist. 
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